| ID Source | ID |
|---|---|
| PubMed CID | 688670 |
| CHEMBL ID | 1410006 |
| CHEBI ID | 107663 |
| SCHEMBL ID | 4281291 |
| Synonym |
|---|
| OPREA1_516034 |
| SPECTRUM5_000624 |
| BRD-K48629186-001-02-7 |
| OPREA1_832193 |
| DIVK1C_006794 |
| SDCCGMLS-0066575.P001 |
| smr000386953 |
| MLS001049126 , |
| SPECTRUM_000874 |
| SPECTRUM4_001912 |
| NCGC00178838-01 |
| BSPBIO_002062 |
| NCGC00095631-01 |
| KBIO1_001738 |
| KBIO2_001354 |
| KBIO2_003922 |
| KBIOSS_001354 |
| KBIOGR_002531 |
| KBIO3_001562 , |
| KBIO2_006490 |
| SPECTRUM2_000322 |
| SPECPLUS_000698 |
| SPBIO_000323 |
| SPECTRUM3_000591 |
| SPECTRUM1500741 |
| CHEBI:107663 |
| 54401-47-7 |
| AKOS000603362 |
| 6-methoxy-2-(4-methoxyphenyl)chromen-4-one |
| NCGC00095631-02 |
| 6,4'-dimethoxyflavone |
| CHEMBL1410006 |
| 4h-1-benzopyran-4-one, 6-methoxy-2-(4-methoxyphenyl)- |
| HMS2269D13 |
| CCG-38598 |
| SCHEMBL4281291 |
| bdbm49933 |
| 6-methoxy-2-(4-methoxyphenyl)chromone |
| cid_688670 |
| 6-methoxy-2-(4-methoxyphenyl)-1-benzopyran-4-one |
| ANVFDWBCVDQNEZ-UHFFFAOYSA-N |
| Q27185985 |
| sr-01000400466 |
| SR-01000400466-1 |
| SR-01000400466-3 |
| 6-methoxy-2-(4-methoxyphenyl)-4h-chromen-4-one |
| STL513071 |
| CS-0367350 |
| PD001604 |
| Class | Description |
|---|---|
| flavonoids | Any organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them. |
| ether | An organooxygen compound with formula ROR, where R is not hydrogen. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.0009 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.7783 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 2.5119 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 2.5119 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 2.3445 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 0.2133 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| BRCA1 | Homo sapiens (human) | Potency | 0.5623 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 5.0119 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 0.6367 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 2.6651 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 6.0374 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| P53 | Homo sapiens (human) | Potency | 39.8107 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.5012 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 1.0266 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 0.5623 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 3.9811 | 0.0100 | 39.5371 | 1,122.0200 | AID1479 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 2.9093 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 0.2512 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 1.4125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 1.4125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 1.4125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 0.8913 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0388 | 14.3501 | 43.6206 | AID2676 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 2.8184 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 0.7943 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 0.7943 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 12.6728 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | IC50 (µMol) | 67.5470 | 0.1343 | 0.8646 | 2.1450 | AID687017 |
| steroidogenic factor 1 | Homo sapiens (human) | IC50 (µMol) | 67.5470 | 1.8730 | 2.9295 | 3.9860 | AID687018 |
| Cathepsin L2 | Homo sapiens (human) | IC50 (µMol) | 12.0000 | 0.0750 | 2.2141 | 10.0000 | AID1799911 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | EC50 (µMol) | 3.9180 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
| transcription factor p65 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 3.9180 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
| Estrogen receptor beta | Mus musculus (house mouse) | EC50 (µMol) | 3.9180 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
| Estrogen receptor | Mus musculus (house mouse) | EC50 (µMol) | 3.9180 | 0.0590 | 5.5596 | 27.2100 | AID1241 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1860355 | Selectivity index, log ratio of Inhibition of CYP450 in human liver microsomes assessed as inhibition of EpETrE formation in presence of arachidonic acid to Inhibition of CYP450 in human liver microsomes assessed as inhibition of 20-HETE formation in pres | |||
| AID1860353 | Inhibition of CYP450 in human liver microsomes assessed as inhibition of 20-HETE formation at 10 uM in presence of arachidonic acid and NADPH by multi-enzyme assay based LC-MS/MS analysis relative to control | |||
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1860354 | Inhibition of CYP450 in human liver microsomes assessed as inhibition of EpETrE formation at 10 uM in presence of arachidonic acid and NADPH by multi-enzyme assay based LC-MS/MS analysis relative to control | |||
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1799911 | Inhibition Activity Assay from Article 10.1021/cc100076k: \\Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin V inhibitors.\\ | 2010 | Journal of combinatorial chemistry, Sep-13, Volume: 12, Issue:5 | Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin V inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.00) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||